Put the medicine’s full name on the comparison. A quote headed peptide care leaves the product unclear. Ask for the ingredient, brand if there is one, and form, whether that is an injection, tablet, or another preparation. Then ask what status that particular product has. The answer matters before a price becomes useful, especially when different websites use familiar drug names for different preparations.
Keep product names precise
As of November 3, 2026, semaglutide products include Ozempic and Wegovy, and tirzepatide products include Mounjaro and Zepbound. For Wegovy and Zepbound, approved uses include losing weight and keeping it off. Ozempic and Mounjaro have FDA approval for blood-sugar control when treating type 2 diabetes. Each label says who the drug is approved to treat. That approval concerns the named product for its listed uses. It does not endorse peptide care as a whole. The same brand can also have different forms. Keep the complete proposed product on the quote so a comparison does not silently change from one form to another.
- Ask the clinician (doctor, physician assistant, or nurse practitioner) to write the exact name on the care plan. Match that wording when asking the pharmacy or insurer about cost.
- Ask which condition the prescription would treat. Keep the reason beside the product name for the coverage discussion.
- If the name on the price page differs from the proposed prescription, ask for a matching quote before comparing amounts.
Source notes
The source below supports the point above, within its stated limits.
FDA · semaglutide product labelingFDA · tirzepatide product labelingCheck the word generic
A generic copies a brand-name drug. It has FDA approval of its own. It differs from a drug made to order by a compounder. The record was checked November 3, 2026. Neither generic semaglutide nor generic tirzepatide was both FDA-approved and allowed on the US market. Liraglutide was different: approved generics existed, including products labeled for weight management. This does not prove that a given pharmacy has stock. It also does not make a compounded product a generic. Ask which exact approved product a claim refers to rather than relying on the word alone.
- Ask whether the proposed product has an FDA approval record. A medicine name in a listing is not the full answer.
- If a service calls a compounded medicine generic, request a clear explanation of that wording. Keep the compound separate in your comparison.
- Have the dispensing pharmacy confirm the product it plans to supply. Availability and coverage still need their own answers.
Source notes
The source below supports the point above, within its stated limits.
FDA · application recordsFDA · claims about compounded medicinesAsk why compounding is proposed
A compounder prepares medicine for a specific need, in place of a ready-made factory product. As checked November 3, 2026, FDA approval does not cover the compounded drug itself, and FDA does not review its quality, benefit, or safety before marketing. FDA describes a role when someone has a medical need the approved product cannot meet. That is a question about care, separate from the question of price. Ask the clinician to explain the specific reason in plain words.
- Keep the approved product and compounded medicine on separate lines. Similar ingredient wording does not make them the same finished medicine.
- Request the preparing pharmacy’s full name, along with the sender’s name if different. Use the state records to check that name.
- Ask for written details about the proposed compound and a way to discuss concerns. The price comparison can wait for those answers.
- If the proposed product changes, rebuild the comparison around the new name. Ask the pharmacy and insurer to address that version. A quote for the earlier proposal leaves the replacement unresolved, even when the service describes both under the same broad heading.
Source notes
The source below supports the point above, within its stated limits.
FDA · why medicines are compoundedFDA · limits of compounded-drug review